15 pharma trends for 2020Real world evidence, patient centricity and new digital experiences are among the top 15 trends set to change Share X15 pharma trends for 2020https://pharmaphorum.com/views-analysis-digital/15-pharma-trends-for-2020/
How does prevalence affect pricing of rare disease drugs?New research from CRA looks at the relationship between rarity of a disease and the price countries are Share XHow does prevalence affect pricing of rare disease drugs?https://pharmaphorum.com/views-analysis-market-access/prevalence-pricing-rare-disease-drugs/
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. At Share XNine for 2019: how did we do on our predictions, and what does this mean for 2020?https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
Q&A: Zulf Masters on emerging marketsUK-based Masters Speciality Pharma focuses on supplying medicines to developing countries where access to treatments is limited – Share XQ&A: Zulf Masters on emerging marketshttps://pharmaphorum.com/views-analysis-market-access/qa-zulf-masters-on-emerging-markets/
Celltrion gears up for subcutaneous infliximab launch in EuropeCelltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe Share XCelltrion gears up for subcutaneous infliximab launch in Europehttps://pharmaphorum.com/views-analysis-market-access/celltrion-gears-up-for-subcutaneous-infliximab-launch-in-europe/
Investors look ahead to 2020 following briefings from pharma chiefs at Jefferies London conferenceThe great and the good of pharma and biotech descended on London to give investors updates on how Share XInvestors look ahead to 2020 following briefings from pharma chiefs at Jefferies London conferencehttps://pharmaphorum.com/views-and-analysis/investors-look-ahead-to/
Secret US-UK talks on drug pricing revealedDespite the UK still not leaving the European Union – pencilled in for the 31 January 2020 at Share XSecret US-UK talks on drug pricing revealedhttps://pharmaphorum.com/views-analysis-market-access/secret-us-uk-talks-on-drug-pricing-revealed/
Measuring value to ensure access in divisive timesGlobally, balancing rising healthcare costs with the drive for innovation is a political hot potato – is a Share XMeasuring value to ensure access in divisive timeshttps://pharmaphorum.com/views-analysis-market-access/measuring-value-to-ensure-access-in-divisive-times/
Nice numbers at 20: what end-of-life evidence does NICE draw on?NICE may be 20 this year, but its policy on end-of-life (EoL) treatments – where NICE can recommend Share XNice numbers at 20: what end-of-life evidence does NICE draw on?https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-what-end-of-life-evidence-does-nice-draw-on/
